Ted Vandenberg

3.9k total citations
39 papers, 2.0k citations indexed

About

Ted Vandenberg is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ted Vandenberg has authored 39 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 14 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ted Vandenberg's work include Cancer Treatment and Pharmacology (23 papers), Breast Cancer Treatment Studies (12 papers) and Advanced Breast Cancer Therapies (8 papers). Ted Vandenberg is often cited by papers focused on Cancer Treatment and Pharmacology (23 papers), Breast Cancer Treatment Studies (12 papers) and Advanced Breast Cancer Therapies (8 papers). Ted Vandenberg collaborates with scholars based in Canada, United States and United Kingdom. Ted Vandenberg's co-authors include Kathleen I. Pritchard, B. Norris, Kathy S. Albain, Lois E. Shepherd, B. Findlay, Mark N. Levine, Margot J. Burnell, Daniel F. Hayes, Robert B. Livingston and Rita S. Mehta and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Ted Vandenberg

39 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ted Vandenberg Canada	19	1.4k	761	585	381	279	39	2.0k
Elisabet Lidbrink Sweden	24	1.7k 1.2×	832 1.1×	628 1.1×	315 0.8×	343 1.2×	51	2.4k
John F. Sandbach United States	15	1.5k 1.0×	864 1.1×	360 0.6×	661 1.7×	413 1.5×	32	2.4k
Massimo Lopez Italy	21	1.6k 1.1×	516 0.7×	598 1.0×	405 1.1×	207 0.7×	59	2.2k
Yasuo Hozumi Japan	23	964 0.7×	704 0.9×	522 0.9×	328 0.9×	549 2.0×	84	1.9k
Kristi A. Boehm United States	24	1.5k 1.0×	720 0.9×	736 1.3×	495 1.3×	117 0.4×	77	2.3k
G. Peruzzotti Italy	20	1.3k 0.9×	1.2k 1.6×	368 0.6×	460 1.2×	232 0.8×	44	2.1k
D. Amoroso Italy	23	2.0k 1.4×	925 1.2×	791 1.4×	455 1.2×	668 2.4×	104	2.8k
Vernon Harvey New Zealand	22	1.3k 0.9×	489 0.6×	357 0.6×	258 0.7×	163 0.6×	44	1.8k
Giorgio Cocconi Italy	25	1.4k 1.0×	421 0.6×	769 1.3×	431 1.1×	223 0.8×	85	2.2k
Hans‐Joachim Lück Germany	28	1.9k 1.3×	721 0.9×	572 1.0×	395 1.0×	182 0.7×	67	2.9k

Countries citing papers authored by Ted Vandenberg

Since Specialization

Citations

This map shows the geographic impact of Ted Vandenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ted Vandenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ted Vandenberg more than expected).

Fields of papers citing papers by Ted Vandenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ted Vandenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ted Vandenberg. The network helps show where Ted Vandenberg may publish in the future.

Co-authorship network of co-authors of Ted Vandenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Ted Vandenberg. A scholar is included among the top collaborators of Ted Vandenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ted Vandenberg. Ted Vandenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blanchette, Phillip, Melody Lam, Lucie Richard, et al.. (2021). The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. The Breast. 60. 295–301. 4 indexed citations

Blanchette, Phillip, Prakesh S. Shah, Xiang Y. Ye, et al.. (2020). Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis. The Breast. 54. 203–210. 11 indexed citations

Blanchette, Phillip, Melody Lam, Lucie Richard, et al.. (2020). The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. Journal of Geriatric Oncology. 11(7). 1132–1137. 9 indexed citations

Mehta, Rita S., William E. Barlow, Kathy S. Albain, et al.. (2019). Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. New England Journal of Medicine. 380(13). 1226–1234. 78 indexed citations

Vandenberg, Ted, et al.. (2012). Febrile Neutropenia Rates with Adjuvant Docetaxel and Cyclophosphamide Chemotherapy in Early Breast Cancer: Discrepancy between Published Reports and Community Practice—An Opdated Analysis. Current Oncology. 19(6). 332–334. 38 indexed citations

Mehta, Rita S., William E. Barlow, Kathy S. Albain, et al.. (2012). Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. New England Journal of Medicine. 367(5). 435–444. 278 indexed citations

Madarnas, Yolanda, Susan Dent, Andrew Robinson, et al.. (2011). Real-World Experience with Adjuvant FEC-D Chemotherapy in Four Ontario Regional Cancer Centres. Current Oncology. 18(3). 119–125. 31 indexed citations

Chan, Arlene, Shailendra Verma, Sibylle Loibl, et al.. (2011). Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Critical Reviews in Oncology/Hematology. 81(2). 136–150. 13 indexed citations

Pritchard, Kathleen I., Lois E. Shepherd, Judith‐Anne W. Chapman, et al.. (2011). Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14. Journal of Clinical Oncology. 29(29). 3869–3876. 66 indexed citations

10.

Vandenberg, Ted, et al.. (2010). Febrile Neutropenia Rates with Adjuvant Docetaxel and Cyclophosphamide Chemotherapy in Early Breast Cancer: Discrepancy between Published Reports and Community Practice—A Retrospective Analysis. Current Oncology. 17(2). 2–3. 30 indexed citations

11.

Bramwell, V., Kathleen I. Pritchard, Dongsheng Tu, et al.. (2009). A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12). Annals of Oncology. 21(2). 283–290. 32 indexed citations

12.

Provencher, Louise, Louise Yelle, Daniel Rayson, et al.. (2007). P142 Rechallenge of patients previously treated with adjuvant anthracyclines using pegylated liposomal doxorubicin (PLD) with cyclophosphamide (C)as first-line chemotherapy for metastaticbreast cancer (MBC). The Breast. 16. S54–S54. 1 indexed citations

13.

Gelmon, Karen A., Ted Vandenberg, Lawrence Panasci, et al.. (2003). A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129. Annals of Oncology. 14(4). 543–548. 11 indexed citations

14.

Vukelja, S., Vladimir Moiseyenko, Robert Leonard, et al.. (2001). Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: Latest results. Breast Cancer Research and Treatment. 69(3). 6 indexed citations

15.

Norris, B., Kathleen I. Pritchard, K. James, et al.. (2000). Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. Journal of Clinical Oncology. 18(12). 2385–2394. 118 indexed citations

16.

Khoo, K., L. J. Brandes, Leonard Reyno, et al.. (1999). Phase II Trial of N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and Doxorubicin Chemotherapy in Metastatic Breast Cancer: A National Cancer Institute of Canada Clinical Trials Group Study. Journal of Clinical Oncology. 17(11). 3431–3437. 11 indexed citations

17.

Levine, Mark N., V. Bramwell, Kathleen I. Pritchard, et al.. (1998). Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 16(8). 2651–2658. 442 indexed citations

18.

Nabholtz, J.-M., W.R. Bezwoda, David Melnychuk, et al.. (1997). Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.. PubMed. 11(8 Suppl 8). 25–30. 31 indexed citations

19.

Stewart, David J., Elizabeth A. Eisenhauer, Jamey Skillings, et al.. (1992). Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: A National Cancer Institute of Canada Clinical Trials Group Study. Annals of Oncology. 3(3). 201–204. 7 indexed citations

20.

Benoit, Brien G., David Addison, Michael T. Richard, et al.. (1984). Intracarotid Chemotherapy with a Combination of 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-Diaminedichloroplatinum (Cisplatin), and 4'-O-Demethyl-1-O-(4,6-O-2-thenylidene-β-D-glucopyranosyl)epipodophyllotoxin (VM-26) in the Treatment of Primary and Metastatic Brain Tumors. Neurosurgery. 15(6). 828–833. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact